Cabiralizumab
- Product Name
- Cabiralizumab
- CAS No.
- 1613144-80-1
- Chemical Name
- Cabiralizumab
- Synonyms
- Cabiralizumab;Cabiralizumab (anti-CSF1R);Research Grade Cabiralizumab;Research Grade Cabiralizumab (DHC25201)
- CBNumber
- CB98080966
- Formula Weight
- 0
- MOL File
- Mol file
Cabiralizumab Property
- form
- Liquid
- color
- Colorless to light yellow
Cabiralizumab Chemical Properties,Usage,Production
Uses
Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research[1][2][3][4].
in vivo
Cabiralizumab (200-400 μg; i.p.; twice a week for 5 times) (anti-CSF1R) has anti-tumor activity and are inferior at higher doses to lower doses in mice model 3.
| Animal Model: | C57Bl6 male mice model (YUMMER1.7 (UV irradiated derivative of YUMM1.7 carrying a higher number of somatic mutations) or YUMM1.7 (BrafV600E /Pten?/?, Cdkn2a?/?) cells were subcutaneously injected into the left flank) (8-9 week old)[3] |
| Dosage: | 200, 400 μg |
| Administration: | Intraperitoneal injection (i.p.); twice a week for 5 times |
| Result: | In the group treated with higher dose αCSF1R, 55% of mice (11/20) reached endpoint, whereas mice treated with lower dose αCSF1R fared better with 25% (5/20) reaching the endpoint in YUMMER1.7 mice model. Lower αCSF1R dose resulted in improved survival compared to the higher αCSF1R dose in YUMMER1.7 mice model. Treatment with both lower and higher anti-CSF1R dose delayed the tumor growth, but all tumors eventually grew out to endpoint in YUMM1.7 mice model. |
References
[1] Weiss SA, et al. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clin Cancer Res. 2021 Sep 1;27(17):4757-4767. DOI:10.1158/1078-0432.CCR-21-0903
[2] Peyraud F, et al. CSF-1R Inhibitor Development: Current Clinical Status. Curr Oncol Rep. 2017 Sep 5;19(11):70. DOI:10.1007/s11912-017-0634-1
[3] Djureinovic D, et al. A bedside to bench study of anti-PD-1, anti-CD40, and anti-CSF1R indicates that more is not necessarily better. Mol Cancer. 2023 Nov 14;22(1):182.
[4] Arnoletti JP, et al. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation. PLoS One. 2022 Mar 22;17(3):e0265725.
Cabiralizumab Preparation Products And Raw materials
Raw materials
Preparation Products
Cabiralizumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58